Results 61 to 70 of about 55,224 (274)

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology

Nature Communications, 2017
Masitinib is a protein kinase inhibitor that sensitises refractory pancreatic adenocarcinoma cells to treatment with the nucleoside analog gemcitabine.
Kahina Hammam, Magali Saez-Ayala, Etienne Rebuffet, Laurent Gros, Sophie Lopez, Berengere Hajem, Martine Humbert, Emilie Baudelet, Stephane Audebert, Stephane Betzi, Adrien Lugari, Sebastien Combes, Sebastien Letard, Nathalie Casteran, Colin Mansfield, Alain Moussy, Paulo De Sepulveda, Xavier Morelli, Patrice Dubreuil   +18 more
doaj   +1 more source

FANCD2 maintains replication fork stability during misincorporation of the DNA demethylation products 5-hydroxymethyl-2’-deoxycytidine and 5-hydroxymethyl-2’-deoxyuridine

Cell Death and Disease, 2022
Fanconi anemia (FA) is a rare hereditary disorder caused by mutations in any one of the FANC genes. FA cells are mainly characterized by extreme hypersensitivity to interstrand crosslink (ICL) agents.
María José Peña-Gómez, Paula Moreno-Gordillo, Milda Narmontė, Clara B. García-Calderón, Audronė Rukšėnaitė, Saulius Klimašauskas, Iván V. Rosado   +6 more
doaj   +1 more source

FHL2 regulates hematopoietic stem cell functions under stress conditions. [PDF]

, 2015
FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under ...
Chen, J, Fan, R, Hou, Y, Hou, Y, Jiang, Y, Li, L, Li, W, Mittal, N, Peace, D, Qian, Z, Wang, X, Wu, W, Zhu, T   +12 more
core   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Contribution of Cytidine Deaminase to Thymidylate Biosynthesis in Trypanosoma brucei: Intracellular Localization and Properties of the Enzyme

mSphere, 2019
Cytidine deaminase (CDA) is a pyrimidine salvage enzyme that catalyzes cytidine and deoxycytidine hydrolytic deamination to yield uridine and deoxyuridine.
Ana Moro-Bulnes, Víctor M. Castillo-Acosta, Maria Valente, Juana Carrero-Lérida, Guiomar Pérez-Moreno, Luis Miguel Ruiz-Pérez, Dolores González-Pacanowska   +6 more
doaj   +1 more source

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner

Biomedicines, 2022
Treatment of pancreatic ductal adenocarcinoma (PDAC), a dismal disease with poor survival rates, is hampered by the high prevalence of chemotherapy resistance.
C. Arnold Spek, Hella L. Aberson, JanWillem Duitman   +2 more
doaj   +1 more source

Genome-wide DNA hypomethylation and RNA:DNA hybrid accumulation in Aicardi-Goutières syndrome. [PDF]

, 2015
Aicardi-Goutières syndrome (AGS) is a severe childhood inflammatory disorder that shows clinical and genetic overlap with systemic lupus erythematosus (SLE).
Chédin, Frédéric, Hartono, Stella R, Lim, Yoong Wearn, Sanz, Lionel A, Xu, Xiaoqin   +4 more
core   +2 more sources

Combating VEGFA‐siRNA‐Induced Metabolic Reprogramming via Glucose Utilization Deprivation

Advanced Science, EarlyView.
An ionizable lipid nanoparticle co‐delivers VEGFA siRNA and glucose oxidase to tumors to counteract VEGFA knockdown‐induced, glutamine‐driven metabolic compensation. Enzymatic glucose consumption reverses the adaptive pathways and restores metabolism toward baseline, thereby sensitizing tumors to therapy.
Lulu Zheng, Shuai Guo, Yingjixing Luo, Pengfei Wu, Haiyin Yang, Yingqiu Xie, Yuchuan Fan, Qing Liu, Bo Hu, Jia Huang, Yuanyu Huang   +10 more
wiley   +1 more source

Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease

Clinical Epigenetics, 2018
Background Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is ...
Tomasz Dziaman, Daniel Gackowski, Jolanta Guz, Kinga Linowiecka, Magdalena Bodnar, Marta Starczak, Ewelina Zarakowska, Martyna Modrzejewska, Anna Szpila, Justyna Szpotan, Maciej Gawronski, Anna Labejszo, Ariel Liebert, Zbigniew Banaszkiewicz, Maria Klopocka, Marek Foksinski, Andrzej Marszalek, Ryszard Olinski   +17 more
doaj   +1 more source

Spectroscopic and theoretical approaches for studying radical reactions in class I ribonucleotide reductase [PDF]

, 2005
Ribonucleotide reductases (RNRs) catalyze the production of deoxyribonucleotides, which are essential for DNA synthesis and repair in all organisms.
Atkin, Bennati, Bennati, Denysenkov, Ehrenberg, Kolberg, Ling, Mezyk, Milov, Oelgemöller, Schmittel, Sjöberg, Sjöberg, Steenken, Stubbe, Stubbe, Thelander, Thelander   +17 more
core   +2 more sources